- Home
- DVAX vs GOODO Comparison
DVAX vs GOODO Comparison
Compare DVAX & GOODO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DVAX
- GOODO
- Stock Information
- Founded
- DVAX 1996
- GOODO N/A
- Country
- DVAX United States
- GOODO United States
- Employees
- DVAX N/A
- GOODO 72
- Industry
- DVAX Biotechnology: Pharmaceutical Preparations
- GOODO Real Estate
- Sector
- DVAX Health Care
- GOODO Real Estate
- Exchange
- DVAX Nasdaq
- GOODO Nasdaq
- Market Cap
- DVAX 1.2B
- GOODO N/A
- IPO Year
- DVAX 2004
- GOODO N/A
- Fundamental
- Price
- DVAX $10.30
- GOODO $20.14
- Analyst Decision
- DVAX Buy
- GOODO
- Analyst Count
- DVAX 4
- GOODO 0
- Target Price
- DVAX $26.50
- GOODO N/A
- AVG Volume (30 Days)
- DVAX 1.4M
- GOODO N/A
- Earning Date
- DVAX 11-05-2025
- GOODO N/A
- Dividend Yield
- DVAX N/A
- GOODO N/A
- EPS Growth
- DVAX N/A
- GOODO N/A
- EPS
- DVAX N/A
- GOODO N/A
- Revenue
- DVAX $316,268,000.00
- GOODO N/A
- Revenue This Year
- DVAX $23.23
- GOODO N/A
- Revenue Next Year
- DVAX $16.57
- GOODO N/A
- P/E Ratio
- DVAX N/A
- GOODO N/A
- Revenue Growth
- DVAX 26.66
- GOODO N/A
- 52 Week Low
- DVAX $9.20
- GOODO N/A
- 52 Week High
- DVAX $14.63
- GOODO N/A
- Technical
- Relative Strength Index (RSI)
- DVAX 53.79
- GOODO 50.55
- Support Level
- DVAX $10.11
- GOODO $19.85
- Resistance Level
- DVAX $10.58
- GOODO $20.10
- Average True Range (ATR)
- DVAX 0.25
- GOODO 0.11
- MACD
- DVAX 0.00
- GOODO 0.01
- Stochastic Oscillator
- DVAX 63.98
- GOODO 58.67
About DVAX Dynavax Technologies Corporation
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.
About GOODO Gladstone Commercial Corporation 6.00% Series G Cumulative Redeemable Preferred Stock par value $0.001 per share
Gladstone Commercial Corp is a real estate investment trust, which engages in investing and owning net leased industrial, commercial, and retail real property and making long-term industrial and commercial mortgage loans. Its portfolio consists of single-tenant commercial, industrial real properties, and medical properties nationwide. Its principal investment objectives are to generate income from rental properties.